Questionnaire GAD pour l’anxiété

Interprétation du score :

- Inférieur à 15 : pas d’anxiété ou anxiété minimale - Supérieur à 15 : anxiété significative

69

70

1-Wang, L.; Chen, C. The Psychological Impact of Hemodialysis on Patients with Chronic Renal Failure; Polenakovic, M., Ed.; InTech: Vienna, Austria, 2019,978-953-51-0630-2.

2-Hmwe, N.; Pathmawathi, S.; Tan, L.; Chong, W. The effects of accupressure on depression anxiety and stress in patients with hemodialysis. A randomized control trial. Int. J. Nurs. Stud. 2015, 52, 509–518.

3- Fan, L.; Sarnak, M.; Tighiouart, H.; Drew, D.; Kantor, A.; Lou, K.; Sha_, K.; Scott, T.;Weiner, D. Depression and all-cause mortality in haemodialysis

patients. Am. J. Nephrol. 2014, 40, 12–18.

4- Jahromi, M.; Javadpour, S.; Taheri, L.; Poorgholami, F. Effect of nurse-led telephone follow ups (tele-nursing) on depression, anxiety and stress in

haemodialysis patients. Glob. J. Health Sci. 2016, 8, 168–173.

5- Vasilopoulou, C.; Bourtsi, E.; Giaple, S.; Koutelekos, I.; Theofilou, P.; Polikandrioti, M. The Impact of Anxiety and Depression on the Quality of Life of Hemodialysis Patients. Glob. J. Health Sci. 2015, 8, 45–55.

6- Gerogianni KS, Babatsikou PF: Psychological aspects in chronic renal failure. Health Sci J 2014;8:205-214.

7- Gerogianni KG, Babatsikou PF: Identification of stress in chronic haemodialysis. Health Sci J 2013;7:169- 176.

8- Feroze U, Martin D, Kalantar-Zadeh K, Kim JC, Reina-Patton A, Kopple JD: Anxiety and depression in maintenance dialysis patients: preliminary data of a cross-sectional study and brief literature review. J Ren Nutr 2012;22:207-210. 9- Wruk-Złotowska A: Lęki pacjentów dializowanych. Pielęgniarstwo Polskie 2006;2:158-166.

10- Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat RevMicrobiol 2019;17:181–92.

11-Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novelcoronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348(20):1953–66.

12-Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolationof a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl JMed 2012;367(19):1814–20.

71

13-Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, et al.Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med2014;370(26):2499–505.

14-Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirusfrom patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727–33.

15-Wu Y, Ho W, Huang Y, Jin D-Y, Li S, Liu S-L, et al. SARS-CoV-2 is an appropriatename for the new coronavirus. Lancet 2020;395(10228):949–50. 16-Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dyna-mics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med2020;382(13):1199–207.

17-Okada P, Buathong R, Phuygun S, Thanadachakul T, Parnmen S,

WongbootW, et al. Early transmission patterns of coronavirus disease 2019 (COVID-19) in travellers from Wuhan to Thailand, January 2020. Euro Surveill2020;25(8):2000097.

18-CORONAVIRUS–COVID-19–Événements SFD. https://evenements-sfd.fr/coronavirus-covid-19/. Consulté le 7 septembre 2020.

19-bation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020:M20–0504.

20-Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familialcluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395(10223):514–23.

21-Jefferson T, Foxlee R, Del Mar C, Dooley L, Ferroni E, Hewak B, et al. Physicalinterventions to interrupt or reduce the spread of respiratory viruses: syste-matic review. BMJ 2009;339:b3675.

22-Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, William-son BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared withSARS-CoV-1. N Engl J Med 2020.

23-Wang X, Pan Z, Cheng Z. Association between 2019-nCoV trans-mission and N95 respirator use. J Hosp Infect 2020.

72

24-Chen W, Lan Y, Yuan X, Deng X, Li Y, Cai X, et al. Detectable 2019-nCoV viral RNAin blood is a strong indicator for the further clinical severity. Emerg MicrobesInfect 2020;9(1):469–73.

25-Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection ofSARS-CoV-2 in different types of clinical. JAMA ofSARS-CoV-20ofSARS-CoV-20.

26-Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, et al. Characteristics ofocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol 2020.

27-Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asympto-matic proportion of coronavirus disease 2019 (COVID-19) cases on boardthe Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro

Surveill2020;25(10):2000180.

28-Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical charac-teristics of 24 symptomatic infections with COVID-19 screenedamong close contacts in Nanjing, China. Sci China Life Sci 2020:10.

29-Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumedasymptomatic carrier transmission of COVID-19. JAMA 2020:e202565.

30-Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical charac-teristics of coronavirus disease 2019 in China. N Engl J Med 2020.

31-Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors formortality of adult inpatients with COVID-19 in Wuhan, China: a retrospectivecohort study. Lancet 2020;395(10229):1054–62.

32-Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated withacute respiratory distress syndrome and death in patients with

coronavirusdisease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020:e200994.

33-Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.

34-Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 mayplay a role in the respiratory failure of COVID-19 patients. J Med Virol 2020:10.25728.

73

35-Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic

manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMANeurol 2020:10.

36-Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA2020.

37-Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI fea-tures. Radiology 2020:201187.

38-Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristicsof 113 deceased patients with coronavirus disease 2019: retrospective study.BMJ 2020:368.

39-Alerte-anosmie-covid-19.

https://www.snorl.org/category-acces-libre/category-actualites/alerte-anosmie-covid-19-20-mars-2020/Consulté le12 avril 2020.

40-Hwang CS. Olfactory neuropathy in severe acute respiratory syndrome: reportof A case. Acta Neurol Taiwan 2006;15(1):26–8.

41-Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hos-pitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,China. JAMA 2020:e201585.

42-Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507–13. 43-CORONAVIRUS–COVID-19–Événements SFD. https://evenements-sfd.fr/coronavirus-covid-19/. Consulté le 12-avr-2020.

44-Réseau Sentinelles, France.

https://websenti.u707.jussieu.fr/sentiweb/Consultéle 12 avril 2020.

45-Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al.Covid-19 in critically ill patients in the Seattle region–case series. N Engl J Med2020:10.

46-CORONAVIRUS–COVID-19–Événements SFD. https://evenements-sfd.fr/coronavirus-covid-19/. Consulté le 7 SEPTEMBRE 2020.

74

47-Dumas JE. L’enfant anxieux : comprendre la peur de la peur et redonner courage. Bruxelle: De Boeck; 2012.

48-BELON JP. L’anxiété et les troubles anxieux, Actualités pharmaceutiques, Elsevier Masson SAS, 2019.

49-Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5), 2013.

50-Bourin M, Lambert O. Pharmacotherapy of anxious disorders. Hum psychopharmacol 2002;17:383–400.

51-Senon JL, Sechster D, Richard D. Thérapeutiques Psychiatriques. Paris: Hermann; 1995.

52-Ansseau M, Dierick M, Buntinkx F, Cnockaert P, De Smedt J, Van Den Haute M, et al. High prevalence of mental disorders in primary care. J Affect Disord 2004;78:49–55.

53- Craven MA, Bland R. Depression in primary care: current and future challenges. Can J Psychiatry Rev Can Psychiatr 2013;58(8):442–8.

54-Rotge J-Y, Tignol J, Aouizerate B. Prise en charge de la dépression en soins primaires : revue et perspectives. Encephale 2007;33(4–C1):552–60.

55-Murray CJ, Lopez AD. The global burden of disease: a comprehensive assessment of morbidity and disability from disease, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard Univer- sity Press; 1996. 56-Malhi GS, Mann JJ. Depression. Lancet. 2018 Nov 24;392(10161):2299-2312

57-Pedersen CB, Mors O, Bertelsen A, Waltoft BL, Agerbo E, McGrath JJ, Mortensen PB, Eaton WW. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry. 2014 May;71(5):573-81.

58-Lyness JM, Niculescu A, Tu X, Reynolds CF, Caine ED. The relationship of medical comorbidity and depression in older, primary care

75

59-Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry. 2009 Sep;70(9):1219-29.

60-Cuijpers P, van Straten A, Warmerdam L, Andersson G. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. Depress Anxiety. 2009;26(3):279-88.

61-Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004 Mar;20(1):13-20.

62-Direction des hôpitaux et des soins ambulatoires, ministère de la Sante´ . Lettre Magredial no 2; 2005.

63- Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005;20:2587–93.

64-Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. World- wide access to treatment for end-stage kidney disease: a systematic review. Lancet Lond Engl 2015;385:1975–82.

65-Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Compari- son of mortality in all patients on dialysis, patients on dialysis

awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725–30.

66-Md Zahir, A,Oli , A, Zhou, H, Sang , S, Liu, A, Akbaruddin. Epidemic of COVID-19 in China and associated Psychological Problems .Asian Journal of Psychiatry 51,2020, 102092.

67- Huang, Y., Wang, Y., Wang, H., Liu, Z., Yu, X., Yan, J., et al., 2019. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry 6 (3),

211–224.

68- Xiang, Y.T., Yang, Y., Li, W., Zhang, Q., Cheung, T., Hg, C.H., 2020. Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. Lancet Psychiatry 7(3), 228–229.

69- Liu, S., Yang, L., Zhang, C., Xiang, Y.-T., Liu, Z., Hu, S., Zhang, B., 2020. Online mental health services in China during the COVID-19 outbreak. Lancet Psychiatry 7, 17–18

76

70- Foa, E.B., Street, G.P., 2001. Women and traumatic events. J. Clin. Psychiatry 62 (Suppl.

17), 29–34.

71-Selçuk Özdin and Şükriye Bayrak Özdin. Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: The importance of gender. International Journal of Social Psychiatry 2020, Vol. 66(5) 504–511.

72- Zhang J-J, Dong X, Cao Y-Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;00:1–12.

73-Vasilopoulou, C.; Bourtsi, E.; Giaple, S.; Koutelekos, I.; Theofilou, P.; Polikandrioti, M. The Impact of Anxiety and Depression on the Quality of Life of Hemodialysis Patients. Glob. J. Health Sci. 2015, 8, 45–55.

74-Nagler EV, Webster AC, Vanholder R et al. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol. Dial. Transplant. 2012;

27: 3736–45.

75- Cuiyan Wang, et al., A longitudinal study on the mental health of general population during the COVID-19 epidemic in China. Brain, Behavior, and Immunity, 2020, 04, 028.